Analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Rating) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Price Performance
Shares of Brooklyn ImmunoTherapeutics stock opened at $0.21 on Monday. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10. The business has a 50-day moving average of $3.78 and a two-hundred day moving average of $2.74. The company has a market capitalization of $12.07 million, a P/E ratio of -0.09 and a beta of 4.61.
Hedge Funds Weigh In On Brooklyn ImmunoTherapeutics
A hedge fund recently bought a new stake in Brooklyn ImmunoTherapeutics stock. Lake Street Advisors Group LLC purchased a new position in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX – Get Rating) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,446,417 shares of the company’s stock, valued at approximately $604,000. Lake Street Advisors Group LLC owned 4.16% of Brooklyn ImmunoTherapeutics as of its most recent SEC filing. 26.00% of the stock is owned by institutional investors.
About Brooklyn ImmunoTherapeutics
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
See Also
- Get a free copy of the StockNews.com research report on Brooklyn ImmunoTherapeutics (BTX)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
